Open access
Open access
Powered by Google Translator Translator

TB/Non-TB Mycobacterial Infections

M-A: Treatment outcomes among pregnant patients with multidrug-resistant tuberculosis.

15 Jun, 2022 | 10:47h | UTC

Treatment Outcomes Among Pregnant Patients With Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis – JAMA Network Open

 

Commentary on Twitter

 


Systematic Review: Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.

25 May, 2022 | 10:46h | UTC

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin – Cochrane Library

Summary: Xpert MTB/XDR, a rapid test for resistance to tuberculosis drugs – Cochrane Library

 


Modeling Study: 20% of multi-drug resistant tuberculosis cases in children could be averted by household testing and treatment.

25 May, 2022 | 10:44h | UTC

News Release: 20% of multi-drug resistant tuberculosis cases in children could be averted by household testing and treatment – London School of Hygiene & Tropical Medicine

Original Study: The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study – The Lancet Global Health

Invited Commentary: Investing in drug-resistant tuberculosis household contact management and preventive treatment – The Lancet Global Health

 


WHO calls for shorter drug course for resistant TB.

4 May, 2022 | 11:08h | UTC

WHO calls for shorter drug course for resistant TB – CIDRAP

Rapid communication: Key changes to the treatment of drug-resistant tuberculosis – World Health Organization

 


Review: Anti-tuberculosis treatment strategies and drug development: challenges and priorities.

1 May, 2022 | 23:23h | UTC

Anti-tuberculosis treatment strategies and drug development: challenges and priorities – Nature Reviews Microbiology (if the link is paywalled, try this one)

News Release: A major update on global tuberculosis fight – Hackensack Meridian Health

 

Commentary on Twitter

 


Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.

27 Apr, 2022 | 07:52h | UTC

Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views – Cochrane Library

Summary: Rapid molecular tests for tuberculosis and tuberculosis drug resistance: the views and experiences of people who are tested and healthcare providers – Cochrane Library

Commentary: Molecular tests for TB: Global rollout of rapid molecular tests for tuberculosis over the last 12 years – Liverpool School of Tropical Medicine

 


Drug resistant TB – latest developments in epidemiology, diagnostics and management.

13 Apr, 2022 | 10:09h | UTC

Drug resistant TB – latest developments in epidemiology, diagnostics and management – International Journal of Infectious Diseases

Related:

Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.

WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment

Randomized Trial: 9-month Treatment for Multi-drug Resistant TB is as Effective as 24-month Treatment

Canadian Tuberculosis Standards – 8th Edition.

Guideline: Treatment of Drug-Resistant Tuberculosis

NICE Guideline: Tuberculosis

The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis

Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives

 


Canadian Tuberculosis Standards – 8th Edition.

28 Mar, 2022 | 09:46h | UTC

Homepage: Canadian Tuberculosis Standards – 8th Edition – Canadian Journal of Respiratory, Critical Care, and Sleep Medicine

Preface

Chapter 1: Epidemiology of tuberculosis in Canada
Chapter 2: Transmission and pathogenesis of tuberculosis

Chapter 3: Diagnosis of tuberculosis disease and drug-resistant tuberculosis

Chapter 4: Diagnosis of tuberculosis infection

Chapter 5: Treatment of tuberculosis disease

Chapter 6: Tuberculosis preventive treatment in adults
Chapter 7: Extra-pulmonary tuberculosis

Chapter 8: Drug-resistant tuberculosis

Chapter 9: Pediatric tuberculosis

Chapter 10: Treatment of active tuberculosis in special populations

Chapter 11: Tuberculosis contact investigation and outbreak management

Chapter 12: An introductory guide to tuberculosis care to improve cultural competence for health care workers and public health professionals serving Indigenous Peoples of Canada

Chapter 13: Tuberculosis surveillance and tuberculosis infection testing and treatment in migrants

Chapter 14: Prevention and control of tuberculosis transmission in healthcare settings

Chapter 15: Monitoring tuberculosis program performance

 


Systematic Review: Symptom‐ and chest‐radiography screening for active pulmonary tuberculosis in HIV‐negative adults and adults with unknown HIV status.

28 Mar, 2022 | 08:54h | UTC

Symptom‐ and chest‐radiography screening for active pulmonary tuberculosis in HIV‐negative adults and adults with unknown HIV status – Cochrane Library

Summary: How accurate are asking about symptoms and doing a chest X-ray to screen for tuberculosis of the lungs among adults who are HIV-negative or with unknown HIV status? – Cochrane Library

 


Cochrane Special Collection: Diagnosing tuberculosis.

25 Mar, 2022 | 09:57h | UTC

Diagnosing tuberculosis – Cochrane Library

 


M-A: Tuberculosis screening among HIV-positive inpatients.

25 Mar, 2022 | 08:35h | UTC

Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis – The Lancet HIV

 

Commentary on Twitter

 


RCT: High dose Rifampicin with or without Levofloxacin vs. standard of care for pediatric tuberculous meningitis.

24 Mar, 2022 | 08:12h | UTC

Randomized Clinical Trial of High Dose Rifampicin with or without Levofloxacin versus Standard of Care for Paediatric Tuberculous Meningitis: The TBM-KIDS Trial – Clinical Infectious Diseases

 


New WHO guidelines on the management of tuberculosis in children and adolescents.

22 Mar, 2022 | 09:52h | UTC

WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents – World Health Organization

Commentary: New Children’s TB Guidelines a ‘Game-Changer’ With Non-Invasive Tests, Shortened Treatments – Health Policy Watch

Related: RCT: In children with nonsevere, drug-susceptible tuberculosis, treatment for 4 months is noninferior to treatment for 6 months.

 


A validated score for evaluating spinal instability to assess surgical candidacy in active spinal tuberculosis—an evidence based approach and multinational expert consensus study.

21 Mar, 2022 | 08:21h | UTC

A Validated Score for Evaluating Spinal Instability to Assess Surgical Candidacy in Active Spinal Tuberculosis—An Evidence Based Approach and Multinational Expert Consensus Study – Global Spine Journal

 


Cohort Study: TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area.

16 Mar, 2022 | 08:44h | UTC

TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area – Scientific Reports

 


Review: Mycobacterial skin infection.

14 Mar, 2022 | 00:59h | UTC

Mycobacterial skin infection – Current Opinion in Infectious Diseases

 


RCT: In children with nonsevere, drug-susceptible tuberculosis, treatment for 4 months is noninferior to treatment for 6 months.

10 Mar, 2022 | 11:03h | UTC

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children – New England Journal of Medicine

News Release: Treatment length reduced for children with tuberculosis – University College London

 

Commentary on Twitter

 


Pictorial Review | Extrapulmonary tuberculosıs: an old but resurgent problem.

9 Mar, 2022 | 08:33h | UTC

Extrapulmonary tuberculosıs: an old but resurgent problem – Insights into Imaging

 


New CDC interim guidance recommends a 4-month Rifapentine-Moxifloxacin regimen to treat drug-susceptible pulmonary tuberculosis.

27 Feb, 2022 | 22:49h | UTC

Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022 – CDC Morbidity and Mortality Weekly Report

Related:

Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.

WHO Guideline: Screening for Tuberculosis Disease

New WHO Recommendations to Prevent Tuberculosis

CDC Guidelines for the Treatment of Latent Tuberculosis Infection

Guideline: Treatment of Drug-Resistant Tuberculosis

NICE Guideline: Tuberculosis

The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis

Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives

Guidelines for the Management of TB in Adults Living with HIV

 

Commentary on Twitter

 


Essay: Tuberculosis in times of COVID-19.

15 Feb, 2022 | 10:16h | UTC

Tuberculosis in times of COVID-19 – Journal of Epidemiology & Community Health

Related:

Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.

Global tuberculosis progress reversed by COVID-19 pandemic.

WHO Report: Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic.

How COVID is derailing the fight against HIV, TB and malaria.

How COVID hurt the fight against other dangerous diseases

World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis

WHO: Benefits of continuing to provide life-saving HIV services outweigh the risk of COVID-19 transmission by 100 to 1

Tuberculosis and Covid-19: Fighting a deadly syndemic

Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study

 


Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments.

11 Feb, 2022 | 08:29h | UTC

Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments – European Respiratory Review

 


Systematic Review: Video-observed therapy vs. directly observed therapy in patients with tuberculosis.

9 Feb, 2022 | 08:35h | UTC

Video-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis – American Journal of Preventive Medicine (link to abstract – $ for full-text)

Related: RCT: Electronic directly observed therapy is noninferior to in-person observed therapy for ensuring adherence to tuberculosis treatment.

 

Commentary on Twitter

 


Cluster-Randomized Trial: A multicomponent diagnostic strategy (on-site molecular testing for tuberculosis, guided restructuring of clinic workflows, and monthly feedback of quality metrics) significantly improved the rates of a confirmed diagnosis of tuberculosis within 14 days after presentation.

8 Feb, 2022 | 08:43h | UTC

Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT: Electronic directly observed therapy is noninferior to in-person observed therapy for ensuring adherence to tuberculosis treatment.

26 Jan, 2022 | 01:58h | UTC

In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial – JAMA Network Open

 

Commentary on Twitter

 


Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.

11 Jan, 2022 | 01:33h | UTC

Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery – New England Journal of Medicine

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.